ArticleFrontiers in oncology2025
Clinical application of confocal laser endomicroscopy in the diagnosis of malignant pleural effusion.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Probe-based confocal laser endomicroscopy (pCLE) is an innovative Methods: A total of 41 patients with pleural effusion (PE) who underwent pCLE examination were enrolled in this prospective study. The diagnostic performance of pCLE was assessed by calculating sensitivity (SEN), specificity (SPE), positive predictive value (PPV), negative predictive value (NPV), and accuracy (ACC), using histopathological results as the reference standard. Additionally, the safety profile of the pCLE procedure was evaluated. Results: Among the 41 patients, histopathological analysis confirmed MPE in 31 patients and benign pleural effusion (BPE) in 10 patients. Of the 31 MPE cases, 26 were lung adenocarcinoma (LUAD), 2 were lung squamous cell carcinoma (LSCC), 1 was large cell lung cancer (LCLC, a subtype of non-small cell lung cancer [NSCLC]), 1 was pleural malignant mesothelioma (PMM), and 1 was pleural metastasis from other tumors. Compared with histopathology, pCLE demonstrated a sensitivity of 96.77%, specificity of 80%, accuracy of 92.68%, PPV of 93.75%, and NPV of 88.89%. There was substantial agreement between pCLE and histopathological findings (kappa = 0.79, p < 0.001). Furthermore, compared to conventional thoracoscopy, pCLE facilitated targeted biopsy sampling and improved detection of malignant lesions. No adverse events related to pCLE were observed, indicating its favorable safety profile. Conclusions: Our study demonstrates that pCLE is a valuable tool for enhancing the diagnosis of MPE, with high concordance with histopathological findings (kappa = 0.79, p < 0.001) and significant guidance for thoracoscopic pleural biopsies. The diagnostic sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of pCLE were 96.77%, 80%, 92.68%, 93.75%, and 88.89%, respectively, when compared with histopathology. These results indicate that pCLE can effectively differentiate between benign and malignant pleural effusion in patients with undetermined etiology and serves as a robust complementary method to existing diagnostic approaches. However, the small sample size of this study limits the generalizability of the findings, and further large-scale, multicenter clinical trials are needed to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.